Graphic: This Is How Sovaldi Price-Gouging Is Costing Lives
Gilead Sciences is making big bucks from a drug that is priced too high for many hep C sufferers to access.
This week the pharmaceutical manufacturer Gilead Sciences released its second quarter earnings, showing sales for the new hepatitis C drug Sovaldi reaching $3.5 billion—a 52% increase in just three months. Small-scale trials suggest that when taken in combination with Olysio, another new antiviral, Sovaldi can effectively cure 90% of hep C cases. But the drug is prohibitively priced—at $1,000 per pill in the US—leading to rationing and restrictions by insurance companies.
You Might Also Like
Check out this interactive feature to get a unique sense of the current numbers—based on data from SAMHSA, the CDC and the FBI—for drug use, drug problems and more.... Read More
Recent media reports have given significant attention to the spread of opioid addiction in suburban America. We can no longer view drug addiction as an inner-city issue that affects a small portion... Read More
The photo of me after my arrest for heroin possession shows the generic "ugly, addicted criminal." That was five years—and a lifetime—ago, but whenever it's republished I feel the same old shame, remorse and dehumanization. Society wants me to.... Read More
We're winning: More progress has been made toward enlightened drug policies and treatment in the past five years than in the previous 25. Here's an advocacy agenda to take us even closer to the future we need.... Read More
Formed to fight for "nothing about us without us" and promote health, drug user unions foster solidarity and some schisms. They're meeting in Baltimore next week to hammer out a national plan.... Read More